Regular readers of this site will recognize the theme of this post before I even get into it — muscle preservation has come up repeatedly, from the very first post I wrote here through the healthspan piece and the discussion of chronic inflammation. I've been building toward this post the whole time. It's time to explain, properly and from the ground up, why muscle occupies such a central place in how I think about metabolic health.
Muscle is not just about strength
Most people think of muscle mass in terms of strength and appearance. Both are real benefits, but they're not why I spend so much time on this topic clinically. Muscle tissue is one of the most metabolically active tissues in the body — meaning it consumes a meaningful share of your resting energy expenditure and plays a direct, active role in regulating blood sugar.
Skeletal muscle is the primary site where your body disposes of glucose after eating. When you eat carbohydrates, a large share of that glucose gets taken up and stored in muscle tissue, largely regulated by insulin. The more muscle mass you have, the more capacity you have to handle glucose efficiently. This is a direct, mechanical link between muscle mass and insulin sensitivity — one of the core threads running through the entire metabolic disease picture I've described in this series.
This means muscle isn't just cosmetic or performance-related. It's functionally protective against the exact dysregulation — insulin resistance, elevated blood sugar — that defines so much of metabolic disease.
Sarcopenia: muscle loss as its own condition
Sarcopenia is the clinical term for age-related, progressive loss of muscle mass and strength. It's often thought of as an inevitable, unremarkable part of aging, but I'd push back on that framing. Left unaddressed, sarcopenia meaningfully accelerates metabolic decline, increases fall and fracture risk, and reduces functional independence — it's a real driver of poor healthspan, not just a cosmetic consequence of getting older.
What makes sarcopenia particularly important for this site's audience is that it isn't only age-related. Rapid weight loss — the exact scenario many patients are in when starting a GLP-1 — can accelerate muscle loss significantly if it isn't actively counteracted. This is the concept I introduced in the very first post on this site: without deliberate intervention, a meaningful share of weight lost on a GLP-1 comes from muscle rather than fat. That's essentially an accelerated, medication-induced version of the same process that happens more gradually with age.
How muscle loss connects to everything else in this series
This is worth being explicit about, because it ties together nearly every concept covered so far:
Muscle loss worsens insulin resistance, which is a core driver of metabolic syndrome — described in an earlier post — since less muscle mass means less capacity to clear glucose from the bloodstream.
Chronic inflammation actively undermines muscle maintenance. I mentioned this briefly in the inflammation post — persistent low-grade inflammation interferes with the body's ability to build and repair muscle tissue, creating a self-reinforcing cycle: less muscle contributes to more metabolic dysfunction, which contributes to more inflammation, which further undermines muscle.
Visceral fat and muscle loss often occur together. As muscle mass declines, particularly with inactivity, the body's tendency to store excess energy as visceral fat rather than lean tissue tends to increase — part of why body composition, not weight, is the more meaningful marker to track.
Why I track this directly, rather than assuming it
This is the clinical practice I described early on in this site: I send patients for DEXA scans between visits specifically because muscle mass doesn't show up reliably on a scale, and it often doesn't show up in how a patient looks, either. A patient can lose visible size while losing a concerning share of muscle mass in the process — the two aren't the same thing, and only direct measurement can tell them apart.
This matters most for patients on GLP-1 therapy, since the appetite suppression that makes these medications so effective can also make it harder to get adequate protein intake, and the significant, sometimes rapid weight loss creates real risk for muscle loss if it isn't actively protected against through resistance training and nutrition.
Where this leads next
In the next post, I'll cover the other half of this picture: fitness — specifically cardiorespiratory fitness — as an independent metabolic marker in its own right, separate from muscle mass and separate from weight. Together, muscle mass and fitness round out the Foundations series with the two factors I think are most consistently underweighted relative to how much they actually predict long-term metabolic health.
Curious what your own muscle mass and body composition actually look like? [Reach out / subscribe / etc. — placeholder for your CTA.]
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.